logo
Northern pins reliability hopes on new trains

Northern pins reliability hopes on new trains

Yahoo07-05-2025

The reliability of rail operator Northern will improve when up to 450 new trains start to come into service at the end of the decade, bosses have claimed.
The company's regional stakeholder manager Owain Roberts, quizzed by BBC Radio Cumbria listeners on Wednesday, said he was "very, very sorry" passengers had experienced high numbers of cancellations over recent years.
Earlier this year, the publicly-owned operator invited manufacturers to begin negotiations for supplying new trains to run across the north of England.
Mr Roberts said the new trains would be a "game changer" but admitted: We still have a long way to go."
"That's no excuse or consolation for customers who's journeys are being disrupted," Mr Roberts said on BBC Radio Cumbria's Hotseat programme.
Northern Trains is owned by the Department for Transport through a holding company [PA]
In July, the company was issued a "breach notice" by the Department for Transport for cancelling too many trains.
Performance figures for April showed about 64% of services ran on time.
In its latest improvement plan, Northern said that by 2027 it wanted 90% of its trains to be on time, with only 2% cancellations.
Mr Roberts said some routes, including the Cumbrian Coast Line, get "battered by the weather".
He said single track sections meant, even if there is just one cancellation, users could "potentially be waiting two hours for a train".
The company is working with Network Rail to improve infrastructure following recent issues, including on the Furness Line which has seen sinkholes, landslips and floods, Mr Roberts said.
Mental health support
The rail boss said 60% of Northern's fleet was between 32 and 40 years old and those carriages operated in various parts of the region, including on the Tyne Valley route.
"They are reaching the end of their lives," Mr Roberts said.
Tenders were submitted in January for a mix of electric and multi-modal (diesel/electric) powered trains to enter service in 2030.
"They will be fantastic when they arrive," Mr Roberts said.
He also told listeners that train crew availability was "less of an issue than at the end of last year".
He said Northern had worked to improve its "pipeline of training" and insisted it had "enough drivers within the business to operate the train plan".
It was also working on "suppressing sickness levels" by partnering with mental health support groups like Andy's Man Club to encourage people to "work through their issues and to promote good wellbeing".
He said mental health issues were affecting society and were "not just within railways".
Follow BBC Cumbria on X, Facebook, Nextdoor and Instagram.
More on this story
Related internet links

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Anteris Appoints David Roberts and Gregory Moss to its Board of Directors
Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

Yahoo

time4 hours ago

  • Yahoo

Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

New Directors Bring Extensive NASDAQ Expertise Across Legal, Operational and Corporate Leadership Capacities MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. 'On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company' commented John Seaberg, Chairman of Anteris. 'On the heels of our Q4 2024 listing onto NASDAQ, and as we ramp-up activities to launch the DurAVR® THV global, pivotal clinical trial (the "PARADIGM Trial"), we are excited to enhance the leadership team with two highly accomplished, U.S. based, healthcare executives as the company transitions to its next phase of growth. I also wish to extend gratitude to Dr. Gu for his commitment and contributions to the company over the course of his tenure as a member of the Board and wish him well on his future endeavors.' Mr. David Roberts is currently President of LeMaitre Vascular, Inc. (NASDAQ: LMAT), a position he has held since 2007. He joined LeMaitre in 1997 as Vice President of Business Development and was promoted to Chief Financial Officer in 2000. Prior to LeMaitre, Mr. Roberts served as Vice President of Development for BUCA, Inc. from 1994 to 1997, and prior to that as Associate of HarbourVest Partners from 1992 to 1994. Mr. Roberts received a Bachelor of Arts in Business Economics and History from Brown University and a Master of Business Administration from the Stanford University Graduate School of Business. Mr. Roberts serves as a director of LeMaitre Vascular, Inc., Lexington Medical, Inc. and Parasole Restaurant Holdings, Inc. Mr. Gregory Moss serves as Chief Business and Legal Officer, as well as Corporate Secretary and Chief Compliance Officer of Evommune, Inc. Prior to Evommune, Mr. Moss served as Executive Vice President, General Counsel, and Corporate Secretary, Chief Compliance Officer at Kadmon, a Sanofi Company, where he led legal, compliance, and business development operations, culminating in Kadmon's $1.9 billion acquisition in 2021. Prior to joining Kadmon in 2012, Mr. Moss served as a solicitor in the corporate risk department of a large Australian law firm and as an associate at a boutique law firm and hedge fund in New York, where he focused on complex litigation and event-driven outcomes. Mr. Moss currently serves on the board of Vitls, Inc. Mr. Moss earned a BA and an LLB from Macquarie University, Australia, and is a member of the Bar Associations of New York, USA, and New South Wales, Australia, with admissions before the Supreme Court of the United States of America; Southern District of New York; Supreme Court of New South Wales, Australia; and High Court of Australia. Mr. Roberts and Mr. Moss will help guide Anteris through its next phase of growth, with the upcoming global pivotal PARADIGM study in 3Q2025 towards the ultimate U.S. and EMA licensure of the DurAVR® THV for patients with aortic stenosis. About Anteris Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients. Anteris' lead product, the DurAVR® Transcatheter Heart Valve (THV), was designed in partnership with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris' patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System. For more information: Investor Relations investor@ OrmsbyAnteris Technologies Global Corp.+61 1300 550 310 | +61 7 3152 3200 Investor Relations (US)mchatterjee@ Chatterjee, Life Science Group+1 917 330 4269WebsiteXFacebookLinkedIn in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Anteris Appoints David Roberts and Gregory Moss to its Board of Directors
Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

Yahoo

time4 hours ago

  • Yahoo

Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

New Directors Bring Extensive NASDAQ Expertise Across Legal, Operational and Corporate Leadership Capacities MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. 'On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company' commented John Seaberg, Chairman of Anteris. 'On the heels of our Q4 2024 listing onto NASDAQ, and as we ramp-up activities to launch the DurAVR® THV global, pivotal clinical trial (the "PARADIGM Trial"), we are excited to enhance the leadership team with two highly accomplished, U.S. based, healthcare executives as the company transitions to its next phase of growth. I also wish to extend gratitude to Dr. Gu for his commitment and contributions to the company over the course of his tenure as a member of the Board and wish him well on his future endeavors.' Mr. David Roberts is currently President of LeMaitre Vascular, Inc. (NASDAQ: LMAT), a position he has held since 2007. He joined LeMaitre in 1997 as Vice President of Business Development and was promoted to Chief Financial Officer in 2000. Prior to LeMaitre, Mr. Roberts served as Vice President of Development for BUCA, Inc. from 1994 to 1997, and prior to that as Associate of HarbourVest Partners from 1992 to 1994. Mr. Roberts received a Bachelor of Arts in Business Economics and History from Brown University and a Master of Business Administration from the Stanford University Graduate School of Business. Mr. Roberts serves as a director of LeMaitre Vascular, Inc., Lexington Medical, Inc. and Parasole Restaurant Holdings, Inc. Mr. Gregory Moss serves as Chief Business and Legal Officer, as well as Corporate Secretary and Chief Compliance Officer of Evommune, Inc. Prior to Evommune, Mr. Moss served as Executive Vice President, General Counsel, and Corporate Secretary, Chief Compliance Officer at Kadmon, a Sanofi Company, where he led legal, compliance, and business development operations, culminating in Kadmon's $1.9 billion acquisition in 2021. Prior to joining Kadmon in 2012, Mr. Moss served as a solicitor in the corporate risk department of a large Australian law firm and as an associate at a boutique law firm and hedge fund in New York, where he focused on complex litigation and event-driven outcomes. Mr. Moss currently serves on the board of Vitls, Inc. Mr. Moss earned a BA and an LLB from Macquarie University, Australia, and is a member of the Bar Associations of New York, USA, and New South Wales, Australia, with admissions before the Supreme Court of the United States of America; Southern District of New York; Supreme Court of New South Wales, Australia; and High Court of Australia. Mr. Roberts and Mr. Moss will help guide Anteris through its next phase of growth, with the upcoming global pivotal PARADIGM study in 3Q2025 towards the ultimate U.S. and EMA licensure of the DurAVR® THV for patients with aortic stenosis. About Anteris Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients. Anteris' lead product, the DurAVR® Transcatheter Heart Valve (THV), was designed in partnership with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris' patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System. For more information: Investor Relations investor@ OrmsbyAnteris Technologies Global Corp.+61 1300 550 310 | +61 7 3152 3200 Investor Relations (US)mchatterjee@ Chatterjee, Life Science Group+1 917 330 4269WebsiteXFacebookLinkedIn

Oppose Car Bloat, London Assembly Members Tell Mayor
Oppose Car Bloat, London Assembly Members Tell Mayor

Forbes

time15 hours ago

  • Forbes

Oppose Car Bloat, London Assembly Members Tell Mayor

Old Mini next to new Mini. CarSized/montage A majority of Members of the London Assembly—the 25-member elected body that scrutinizes the work of the London Mayor—voted on June 5 to oppose 'carspreading,'the phenonomen of automobiles becoming wider, heavier and taller. This car bloat, also known as 'autobesity,' damages London's roads, said the vote, causing congestion, and putting pedestrians, cyclists and other drivers at greater risk of death and serious injury. Cars are getting bigger by an average of 1cm every two years, with most new cars now too large for U.K. minimum parking spaces. Elly Baker AM, who proposed the motion, said: 'London's streets weren't designed for larger vehicles like SUVs, which now make up a third of all cars on the road. Their greater size, weight, and higher [hoods] put vulnerable road users at greater risk, reduce available parking spaces, and cause more wear and tear on our roads.' She added: 'It's time we took sensible steps to manage the impact of oversized cars and ensure our streets remain safe and accessible for everyone.' The vote was won by 14 votes against eight. The motion states that the 'consequences of surging vehicle size undermine goals for road safety, air quality and put outsized pressure on public finances.' The Assembly now calls on the Mayor to write to the Department for Transport asking that they update vehicle regulations to introduce tighter limits on passenger vehicle size and bonnet height. The Mayor is further urged to write to HM Treasury asking that they introduce a progressive tax on passenger vehicle weight into Vehicle Excise Duty. The Assembly is also calling for London Councils to explore the feasibility of boroughs charging higher parking charges to SUVs to account for pressure they put on road space and local parking spaces. Today's BMW-built Mini is much wider than the British Motor Corporation's 1959 original, and is also taller and longer. Other famous car models—such as the VW Beetle and the Ford Fiesta—have also increased markedly in size and weight. Modern cars are larger partly because of airbags, crumple zones and air conditioning units, but also because consumers prefer larger motor vehicles—hence the success of SUVs. The motor vehicle 'arms race' has led to calls from motorists for road lanes to be widened and parking spaces to be enlarged. Roads in most British cities are becoming more and more choked as wider motor cars struggle to squeeze past each other. There's an epidemic of pedestrian-unfriendly 'pavement parking'—wheels half up on the sidewalk—and tempers fray when wing mirrors are bashed as porkier cars pass each other. Research from Transport & Environment (T&E) in 2022 found that 'autobesity'—car bloat—is real, with many cars getting too big for British roads, exceeding the 180 centimeter minimum for on-street parking. More than half of new cars sold in 2023 were too wide for the minimum specified on-street parking space (180 centimeters) in major U.K. cities. Off-street parking is now a tight squeeze even for the average new car, while large luxury SUVs often make it impossible. Fatter cars are heavier cars. And heavier cars cause more highway damage. Richard Hebditch, UK Director for T&E UK, said: 'The trend of cars getting wider has been progressing for decades and that trend will continue until the U.K. sets stricter limits. Currently we allow new cars to be as wide as trucks. This has meant our roads are now home to big SUVs and American style pick-up trucks that are parking on our footpaths, endangering pedestrians and cyclists and making everyone else on our roads less safe.' Paris voted to triple parking fees for SUVs in February last year.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store